This trial will compare quality of life in patients with atrial fibrillation who undergo electrical cardioversion to those who undergo a sham procedure.
1 Primary · 4 Secondary · Reporting Duration: 4 weeks
Absolute AFEQT score post-cardioversion
Change in daily activity
Change in generic quality of life
Difference between AFEQT Scores pre and post cardioversion
Study exit questionnaire on patient's perceived well-being
2 Treatment Groups
1 of 2
1 of 2
100 Total Participants · 2 Treatment Groups
Primary Treatment: Electrical cardioversion · Has Placebo Group · N/A
ProcedureExperimental Group · 1 Intervention: Electrical cardioversion · Intervention Types: Procedure
OtherShamComparator Group · 1 Intervention: Sham electrical cardioversion · Intervention Types: Other
Drug Approval Stage
How many patients have taken this drug
Screening: ~3 weeks
Reporting: 4 weeks
Who is running the clinical trial?
Ottawa Heart Institute Research CorporationLead Sponsor
181 Previous Clinical Trials
91,248 Total Patients Enrolled
23 Trials studying Atrial Fibrillation
6,591 Patients Enrolled for Atrial Fibrillation
David Birnie, MDPrincipal InvestigatorOttawa Heart Institute Research Corporation
4 Previous Clinical Trials
3,147 Total Patients Enrolled
Age 18+ · All Participants · 2 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
You have ongoing atrial fibrillation.
We don't know how much your symptoms are related to atrial fibrillation.
Frequently Asked Questions
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there vacancies remaining in this clinical assessment?
"According to the clinicaltrials.gov records, this trial is not actively seeking patients; it was first posted on December 20th 2022 and last edited November 18th 2022. Nonetheless, there are currently 477 different studies that are open for enrollment right now." - Anonymous Online Contributor